PortfoliosLab logoPortfoliosLab logo
GNOM vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

GNOM vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Global X Genomics & Biotechnology ETF (GNOM) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GNOM achieves a 7.81% return, which is significantly lower than IDNA's 10.31% return.


GNOM

1D
1.99%
1M
5.82%
YTD
7.81%
6M
6.65%
1Y
54.21%
3Y*
-0.94%
5Y*
-10.20%
10Y*

IDNA

1D
0.73%
1M
-2.56%
YTD
10.31%
6M
8.52%
1Y
40.87%
3Y*
6.74%
5Y*
-8.42%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

GNOM vs. IDNA - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
GNOM
Global X Genomics & Biotechnology ETF
7.81%18.65%-15.99%-8.63%-36.27%-15.93%51.52%9.51%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
10.31%17.26%-0.72%-7.63%-42.28%-3.98%54.30%20.83%

Correlation

The correlation between GNOM and IDNA is 0.87, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.87

Correlation (3Y)
Calculated over the trailing 3-year period

0.88

Correlation (5Y)
Calculated over the trailing 5-year period

0.90

Correlation (All Time)
Calculated using the full available price history since Jun 14, 2019

0.89

The correlation between GNOM and IDNA has been stable across timeframes, ranging from 0.87 to 0.90 - a consistent structural relationship.

GNOM vs. IDNA - Sectors Allocation Comparison


Sectors
GNOM
IDNA

Healthcare

99.6%
97.8%

Technology

0.4%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

-

Industrials

-

0.4%

Real Estate

-

-

Utilities

-

-

Healthcare

GNOM
99.6%
IDNA
97.8%

Technology

GNOM
0.4%
IDNA

-

Basic Materials

GNOM

-

IDNA

-

Communication Services

GNOM

-

IDNA

-

Consumer Cyclical

GNOM

-

IDNA

-

Consumer Defensive

GNOM

-

IDNA

-

Energy

GNOM

-

IDNA

-

Financial Services

GNOM

-

IDNA

-

Industrials

GNOM

-

IDNA
0.4%

Real Estate

GNOM

-

IDNA

-

Utilities

GNOM

-

IDNA

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GNOM vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOM
GNOM Risk / Return Rank: 5757
Overall Rank
GNOM Sharpe Ratio Rank: 6060
Sharpe Ratio Rank
GNOM Sortino Ratio Rank: 6161
Sortino Ratio Rank
GNOM Omega Ratio Rank: 5353
Omega Ratio Rank
GNOM Calmar Ratio Rank: 6060
Calmar Ratio Rank
GNOM Martin Ratio Rank: 5151
Martin Ratio Rank

IDNA
IDNA Risk / Return Rank: 5555
Overall Rank
IDNA Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 4949
Sortino Ratio Rank
IDNA Omega Ratio Rank: 4242
Omega Ratio Rank
IDNA Calmar Ratio Rank: 7676
Calmar Ratio Rank
IDNA Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNOM vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GNOMIDNADifference

Sharpe ratio

Return per unit of total volatility

2.06

1.68

+0.38

Sortino ratio

Return per unit of downside risk

2.91

2.44

+0.47

Omega ratio

Gain probability vs. loss probability

1.33

1.27

+0.06

Calmar ratio

Return relative to maximum drawdown

3.00

3.85

-0.85

Martin ratio

Return relative to average drawdown

8.62

10.98

-2.36

GNOM vs. IDNA - Sharpe Ratio Comparison

The current GNOM Sharpe Ratio is 2.06, which is comparable to the IDNA Sharpe Ratio of 1.68. The chart below compares the historical Sharpe Ratios of GNOM and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


GNOMIDNADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.06

1.68

+0.38

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.31

-0.30

-0.01

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.09

0.10

-0.19

Drawdowns

GNOM vs. IDNA - Drawdown Comparison

The maximum GNOM drawdown since its inception was -75.00%, which is greater than IDNA's maximum drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for GNOM and IDNA.


Loading charts...

Drawdown Indicators


GNOMIDNADifference

Max Drawdown

Largest peak-to-trough decline

-75.00%

-68.26%

-6.74%

Max Drawdown (1Y)

Largest decline over 1 year

-18.17%

-10.66%

-7.51%

Max Drawdown (3Y)

Largest decline over 3 years

-46.47%

-29.73%

-16.74%

Max Drawdown (5Y)

Largest decline over 5 years

-72.29%

-68.26%

-4.03%

Current Drawdown

Current decline from peak

-55.45%

-45.61%

-9.84%

Average Drawdown

Average peak-to-trough decline

-40.55%

-36.24%

-4.31%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.30%

3.73%

+2.57%

Volatility

GNOM vs. IDNA - Volatility Comparison

Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 8.47% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 7.18%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GNOMIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

8.47%

7.18%

+1.29%

Volatility (6M)

Calculated over the trailing 6-month period

19.44%

17.98%

+1.46%

Volatility (1Y)

Calculated over the trailing 1-year period

26.50%

24.48%

+2.02%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

33.57%

28.42%

+5.15%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

34.17%

29.53%

+4.64%

GNOM vs. IDNA - Expense Ratio Comparison

GNOM has a 0.50% expense ratio, which is higher than IDNA's 0.47% expense ratio.


Dividends

GNOM vs. IDNA - Dividend Comparison

GNOM's dividend yield for the trailing twelve months is around 1.27%, more than IDNA's 1.07% yield.


PositionTTM2025202420232022202120202019
GNOM
Global X Genomics & Biotechnology ETF
1.27%1.37%0.00%0.00%0.00%0.03%0.14%0.00%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.07%1.18%0.98%1.04%0.54%0.70%0.26%0.80%

Frequently Asked Questions


GNOM and IDNA have a correlation of 0.87, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

GNOM has higher volatility (8.47%) compared to IDNA (7.18%). In terms of maximum drawdown, GNOM dropped -75.00% vs IDNA's -68.26%.

On 5-year performance, IDNA leads with -8.42% vs -10.20% for GNOM. On fees, IDNA is cheaper at 0.47% per year. On volatility, IDNA has been the lower-risk option at 7.18%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, IDNA has performed better with a -8.42% return vs -10.20%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IDNA is cheaper with a 0.47% expense ratio, compared with 0.50% for GNOM.

GNOM has the higher dividend yield at 1.27%, compared with 1.07% for IDNA.

GNOM tracks Solactive Genomics Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: Global X and iShares. Their fees differ too: 0.50% for GNOM and 0.47% for IDNA.

GNOM currently has the higher Sharpe Ratio (2.06 vs 1.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GNOM and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer